Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
Status:
Active, not recruiting
Trial end date:
2026-06-26
Target enrollment:
Participant gender:
Summary
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice
daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with
Relapsing Multiple Sclerosis (RMS).
Phase:
Phase 3
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany